Published in Med Phys on November 01, 2009
C-arm Cone-beam CT in Prostate Brachytherapy (C-arm) | NCT02322931
Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia. Int J Radiat Oncol Biol Phys (2010) 1.13
The phylogeny of permanent prostate brachytherapy. J Contemp Brachytherapy (2013) 1.11
Dosimetric effect of tissue heterogeneity for (125)I prostate implants. Rep Pract Oncol Radiother (2014) 0.91
Ultrasound-fluoroscopy registration for prostate brachytherapy dosimetry. Med Image Anal (2012) 0.88
Dosimetric effects of prone and supine positions on post-implant assessments for prostate brachytherapy. J Contemp Brachytherapy (2013) 0.86
Evaluation of the dosimetric impact of loss and displacement of seeds in prostate low-dose-rate brachytherapy. J Contemp Brachytherapy (2015) 0.85
A biodistribution and toxicity study of cobalt dichloride-N-acetyl cysteine in an implantable MRI marker for prostate cancer treatment. Int J Radiat Oncol Biol Phys (2012) 0.85
Case series analysis of post-brachytherapy prostate edema and its relevance to post-implant dosimetry. Post-implant prostate edema and dosimetry. J Contemp Brachytherapy (2012) 0.84
Evaluation of the effect of prostate volume change on tumor control probability in LDR brachytherapy. J Contemp Brachytherapy (2011) 0.84
Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity. Radiat Oncol (2014) 0.83
Time to failure after definitive therapy for prostate cancer: implications for importance of aggressive local treatment. J Contemp Brachytherapy (2013) 0.80
A digital model individual template and CT-guided 125I seed implants for malignant tumors of the head and neck. J Radiat Res (2012) 0.80
Impact of edema and seed movement on the dosimetry of prostate seed implants. J Med Phys (2012) 0.80
Single fraction multimodal image guided focal salvage high-dose-rate brachytherapy for recurrent prostate cancer. J Contemp Brachytherapy (2016) 0.79
Investigating the dosimetric and tumor control consequences of prostate seed loss and migration. Med Phys (2012) 0.79
Effect of a urinary catheter on seed position and rectal and bladder doses in CT-based post-implant dosimetry for prostate cancer brachytherapy. J Contemp Brachytherapy (2015) 0.78
Trends in targeted prostate brachytherapy: from multiparametric MRI to nanomolecular radiosensitizers. Cancer Nanotechnol (2016) 0.75
Technical and dosimetric aspects of iodine-125 seed reimplantation in suboptimal prostate implants. Br J Radiol (2013) 0.75
Reduced dose to urethra and rectum with the use of variable needle spacing in prostate brachytherapy: a potential role for robotic technology. J Contemp Brachytherapy (2015) 0.75
Definition of medical event is to be based on the total source strength for evaluation of permanent prostate brachytherapy: A report from the American Society for Radiation Oncology. Pract Radiat Oncol (2011) 0.75
Prostate cancer treated with brachytherapy; an exploratory study of dose-dependent biomarkers and quality of life. Radiat Oncol (2017) 0.75
Prostate deformation from inflatable rectal probe cover and dosimetric effects in prostate seed implant brachytherapy. Med Phys (2016) 0.75
The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol (1989) 5.78
Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys (1997) 4.73
The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol (1985) 3.17
How low is the alpha/beta ratio for prostate cancer? Int J Radiat Oncol Biol Phys (2003) 2.46
Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol (2007) 2.26
What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys (2003) 1.99
Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. Eur Urol (2007) 1.92
How well is the probability of tumor cure after fractionated irradiation described by Poisson statistics? Radiat Res (1990) 1.83
Biologically effective dose distribution based on the linear quadratic model and its clinical relevance. Int J Radiat Oncol Biol Phys (1995) 1.63
Prostate volume contouring: a 3D analysis of segmentation using 3DTRUS, CT, and MR. Int J Radiat Oncol Biol Phys (2007) 1.59
A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys (1998) 1.51
Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys (2005) 1.42
An 'incomplete-repair' model for survival after fractionated and continuous irradiations. Int J Radiat Biol Relat Stud Phys Chem Med (1985) 1.27
The clinical radiobiology of brachytherapy. Br J Radiol (1998) 1.26
Robotically assisted prostate brachytherapy with transrectal ultrasound guidance--Phantom experiments. Brachytherapy (2006) 1.20
Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: an analysis based on serial CT acquisition. Int J Radiat Oncol Biol Phys (1998) 1.18
Tumour control probability: a formulation applicable to any temporal protocol of dose delivery. Phys Med Biol (2000) 1.18
Incorporation of functional status into dose-volume analysis. Med Phys (1999) 1.17
The linear-quadratic transformation of dose-volume histograms in fractionated radiotherapy. Radiother Oncol (1998) 1.12
Prescription dose in permanent (131)Cs seed prostate implants. Med Phys (2005) 1.11
Robot-assisted 3D-TRUS guided prostate brachytherapy: system integration and validation. Med Phys (2004) 1.10
Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy. Brachytherapy (2003) 1.08
Accuracy of volume and DVH parameters determined with different brachytherapy treatment planning systems. Radiother Oncol (2007) 1.07
Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys (2000) 1.02
Sequential evaluation of prostate edema after permanent seed prostate brachytherapy using CT-MRI fusion. Int J Radiat Oncol Biol Phys (2005) 1.02
Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model. Int J Radiat Oncol Biol Phys (1992) 0.99
A clinical method for real-time dosimetric guidance of transperineal 125I prostate implants using interventional magnetic resonance imaging. Int J Radiat Oncol Biol Phys (2000) 0.99
The low alpha/beta ratio for prostate cancer: what does the clinical outcome of HDR brachytherapy tell us? Int J Radiat Oncol Biol Phys (2003) 0.97
The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants. Int J Radiat Oncol Biol Phys (2003) 0.97
Tissue inhomogeneity correction for brachytherapy sources in a heterogeneous phantom with cylindrical symmetry. Med Phys (1992) 0.96
Impact of intraoperative edema during transperineal permanent prostate brachytherapy on computer-optimized and preimplant planning techniques. Am J Clin Oncol (2003) 0.96
Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys (1995) 0.93
Optimizing target coverage by dosimetric feedback during prostate brachytherapy. Int J Radiat Oncol Biol Phys (2000) 0.93
Dosimetric effects of edema in permanent prostate seed implants: a rigorous solution. Int J Radiat Oncol Biol Phys (2000) 0.92
Impact of interseed attenuation and tissue composition for permanent prostate implants. Med Phys (2006) 0.92
Magnetic resonance spectroscopy-guided transperineal prostate biopsy and brachytherapy for recurrent prostate cancer. Urology (2005) 0.92
Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys (1995) 0.91
Biologically-equivalent dose and long-term survival time in radiation treatments. Phys Med Biol (2007) 0.90
Recommendations of the American Association of Physicists in Medicine on 103Pd interstitial source calibration and dosimetry: implications for dose specification and prescription. Med Phys (2000) 0.90
Interseed effects on dose for 125I brachytherapy implants. Med Phys (1992) 0.89
Postimplant dosimetry using a Monte Carlo dose calculation engine: a new clinical standard. Int J Radiat Oncol Biol Phys (2007) 0.88
Anticipating prostatic volume changes due to prostate brachytherapy. Radiat Oncol Investig (1999) 0.88
Dose escalation in permanent brachytherapy for prostate cancer: dosimetric and biological considerations. Phys Med Biol (2003) 0.87
Impact of postimplant edema on V(100) and D(90) in prostate brachytherapy: can implant quality be predicted on day 0? Int J Radiat Oncol Biol Phys (2002) 0.87
Assessment of i-125 prostate implants by tumor bioeffect. Int J Radiat Oncol Biol Phys (2004) 0.87
Recommendations for permanent prostate brachytherapy with (131)Cs: a consensus report from the Cesium Advisory Group. Brachytherapy (2008) 0.87
Analysis of the radiobiology of ytterbium-169 and iodine-125 permanent brachytherapy implants. Phys Med Biol (1997) 0.86
MCPI: a sub-minute Monte Carlo dose calculation engine for prostate implants. Med Phys (2005) 0.86
Intraoperative optimization of needle placement and dwell times for conformal prostate brachytherapy. Int J Radiat Oncol Biol Phys (1995) 0.84
A Monte Carlo study on the effect of seed design on the interseed attenuation in permanent prostate implants. Med Phys (2008) 0.84
Effect of edema, relative biological effectiveness, and dose heterogeneity on prostate brachytherapy. Med Phys (2006) 0.84
Potential impact of prostate edema on the dosimetry of permanent seed implants using the new 131Cs (model CS-1) seeds. Med Phys (2006) 0.84
Biologically effective dose (BED) for interstitial seed implants containing a mixture of radionuclides with different half-lives. Int J Radiat Oncol Biol Phys (2003) 0.83
CT-based dosimetry calculations for 125I prostate implants. Int J Radiat Oncol Biol Phys (1999) 0.83
Optimum timing for image-based dose evaluation of 125I and 103PD prostate seed implants. Int J Radiat Oncol Biol Phys (1999) 0.83
Fused radioimmunoscintigraphy for treatment planning. Rev Urol (2006) 0.82
Sector analysis of prostate implants. Med Phys (2001) 0.81
A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate carcinoma. Cancer (2002) 0.81
Quantifying the effect of dose inhomogeneity in brachytherapy: application to permanent prostatic implant with 125I seeds. Int J Radiat Oncol Biol Phys (1994) 0.81
The accuracy of single-seed dose superposition for I-125 implants. Med Phys (1989) 0.80
Phantom investigations on CT seed imaging for interstitial brachytherapy. Radiother Oncol (2007) 0.79
The design and testing of a solid phantom for the verification of a commercial 3D seed reconstruction algorithm. Radiother Oncol (2004) 0.78
Biological effective dose for comparison and combination of external beam and low-dose rate interstitial brachytherapy prostate cancer treatment plans. Med Dosim (2004) 0.78
Calculation of integrated biological response in brachytherapy. Int J Radiat Oncol Biol Phys (1997) 0.78
Functional dose-volume histograms for functionally heterogeneous normal organs. Phys Med Biol (1997) 0.78
Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry. Semin Urol Oncol (2000) 0.77
Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol (2010) 6.64
Structural flexibility in the Burkholderia mallei genome. Proc Natl Acad Sci U S A (2004) 4.13
AAPM protocol for 40-300 kV x-ray beam dosimetry in radiotherapy and radiobiology. Med Phys (2001) 3.32
HMGB1 promotes drug resistance in osteosarcoma. Cancer Res (2011) 2.82
Bacterial genome adaptation to niches: divergence of the potential virulence genes in three Burkholderia species of different survival strategies. BMC Genomics (2005) 2.34
Limited resection for non-small cell lung cancer: observed local control with implantation of I-125 brachytherapy seeds. Ann Thorac Surg (2003) 2.16
Sub-telomere directed gene expression during initiation of invasive aspergillosis. PLoS Pathog (2008) 2.09
The incidence of transition zone prostate cancer diagnosed by transperineal template-guided mapping biopsy: implications for treatment planning. Urology (2011) 2.09
Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency. Int J Cancer (2008) 2.09
American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy (2012) 2.03
An early Ediacaran assemblage of macroscopic and morphologically differentiated eukaryotes. Nature (2011) 1.92
Whole-genome sequencing of cultivated and wild peppers provides insights into Capsicum domestication and specialization. Proc Natl Acad Sci U S A (2014) 1.91
Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys (2005) 1.83
Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison. J Nucl Med (2004) 1.81
Contribution of gene loss to the pathogenic evolution of Burkholderia pseudomallei and Burkholderia mallei. Infect Immun (2004) 1.70
Implementing IMRT in clinical practice: a joint document of the American Society for Therapeutic Radiology and Oncology and the American Association of Physicists in Medicine. Int J Radiat Oncol Biol Phys (2004) 1.70
A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat Biotechnol (2010) 1.62
A pilot study to detect high mobility group box 1 and heat shock protein 72 in cerebrospinal fluid of pediatric patients with meningitis. Crit Care Med (2008) 1.62
Incidence and pathological features of prostate cancer detected on transperineal template guided mapping biopsy after negative transrectal ultrasound guided biopsy. J Urol (2013) 1.61
Vessel-sparing prostate radiotherapy: dose limitation to critical erectile vascular structures (internal pudendal artery and corpus cavernosum) defined by MRI. Int J Radiat Oncol Biol Phys (2005) 1.59
Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis. Arch Med Res (2011) 1.55
In vivo cancer diagnosis with optical spectroscopy and acoustically induced blood stasis using a murine MCa35 model. Med Phys (2006) 1.54
Differentiation and integration: guiding principles for analyzing cognitive change. Dev Sci (2008) 1.51
Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland. J Urol (2003) 1.50
Luffa echinata Roxb. induces human colon cancer cell (HT-29) death by triggering the mitochondrial apoptosis pathway. Molecules (2012) 1.48
Treatment margins predict biochemical outcomes after prostate brachytherapy. Cancer J (2004) 1.47
Autophagy regulates myeloid cell differentiation by p62/SQSTM1-mediated degradation of PML-RARα oncoprotein. Autophagy (2011) 1.47
PCB association with model phospholipid bilayers. Environ Sci Technol (2008) 1.42
Long-term rectal function after permanent prostate brachytherapy. Cancer J (2007) 1.42
Biochemical outcome for hormone-naïve patients with high-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external-beam radiation. Cancer J (2002) 1.42
Experimental and clinical observations of 99mTc-MIBI uptake correlate with P-glycoprotein expression in lung cancer. Nucl Med Commun (2007) 1.41
Transcriptional profiling identifies a role for BrlA in the response to nitrogen depletion and for StuA in the regulation of secondary metabolite clusters in Aspergillus fumigatus. Eukaryot Cell (2008) 1.41
Prostate cancer death is unlikely in high-risk patients following quality permanent interstitial brachytherapy. BJU Int (2010) 1.41
Structural basis of effector regulation and signal termination in heterotrimeric Galpha proteins. Adv Protein Chem (2007) 1.40
Iodine 125 versus palladium 103 implants for prostate cancer: clinical outcomes and complications. Cancer J (2004) 1.39
Endovascular brachytherapy for the treatment of renal artery in-stent restenosis using a beta-emitting source: a report of five patients. South Med J (2003) 1.38
The morbidity of transperineal template-guided prostate mapping biopsy. BJU Int (2008) 1.36
Vivo motion and force measurement of surgical needle intervention during prostate brachytherapy. Med Phys (2006) 1.36
The early stage of bacterial genome-reductive evolution in the host. PLoS Pathog (2010) 1.35
A gradient feature weighted Minimax algorithm for registration of multiple portal images to 3DCT volumes in prostate radiotherapy. Int J Radiat Oncol Biol Phys (2006) 1.35
Hypoxia-induced down-regulation of microRNA-34a promotes EMT by targeting the Notch signaling pathway in tubular epithelial cells. PLoS One (2012) 1.34
A dosimetric uncertainty analysis for photon-emitting brachytherapy sources: report of AAPM Task Group No. 138 and GEC-ESTRO. Med Phys (2011) 1.34
Dose calculation for photon-emitting brachytherapy sources with average energy higher than 50 keV: report of the AAPM and ESTRO. Med Phys (2012) 1.31
Genomic insights into salt adaptation in a desert poplar. Nat Commun (2013) 1.30
Third-party brachytherapy source calibrations and physicist responsibilities: report of the AAPM Low Energy Brachytherapy Source Calibration Working Group. Med Phys (2008) 1.29
Beta-TCP bone graft substitutes in a bilateral rabbit tibial defect model. Biomaterials (2008) 1.29
Supplement to the 2004 update of the AAPM Task Group No. 43 Report. Med Phys (2007) 1.28
Towards consensus practices to qualify safety biomarkers for use in early drug development. Nat Biotechnol (2010) 1.25
Single-layered ultrasmall nanoplates of MoS2 embedded in carbon nanofibers with excellent electrochemical performance for lithium and sodium storage. Angew Chem Int Ed Engl (2014) 1.24
Anniversary paper: past and current issues, and trends in brachytherapy physics. Med Phys (2008) 1.23
Regulation of Rho guanine nucleotide exchange factors by G proteins. Adv Protein Chem (2007) 1.23
Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys (2010) 1.22
Monitoring sleepiness with on-board electrophysiological recordings for preventing sleep-deprived traffic accidents. Clin Neurophysiol (2007) 1.21
RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci (2011) 1.19
Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma. Autophagy (2012) 1.19
Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: a multicenter randomized controlled trial. J Integr Med (2013) 1.17
Use and uncertainties of mutual information for computed tomography/ magnetic resonance (CT/MR) registration post permanent implant of the prostate. Med Phys (2005) 1.16
Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review). Oncol Rep (2012) 1.16
Genetic diversity and geographic differentiation in endangered Ammopiptanthus (Leguminosae) populations in desert regions of northwest China as revealed by ISSR analysis. Ann Bot (2005) 1.13
Direct observation of lithium staging in partially delithiated LiFePO4 at atomic resolution. J Am Chem Soc (2011) 1.12
Report of the Task Group 186 on model-based dose calculation methods in brachytherapy beyond the TG-43 formalism: current status and recommendations for clinical implementation. Med Phys (2012) 1.12
Functional anatomy of the prostate: implications for treatment planning. Int J Radiat Oncol Biol Phys (2005) 1.12
The phylogeny of permanent prostate brachytherapy. J Contemp Brachytherapy (2013) 1.11
DAMP-mediated autophagy contributes to drug resistance. Autophagy (2011) 1.10
Identification of nuclear import mechanisms for the neuronal Cdk5 activator. J Biol Chem (2006) 1.08
Honokiol induces apoptosis through p53-independent pathway in human colorectal cell line RKO. World J Gastroenterol (2004) 1.08
Equivalent phantom sizes and shapes for brachytherapy dosimetric studies of 192Ir and 137Cs. Med Phys (2008) 1.08
Development of simple sequence repeat (SSR) markers from a genome survey of Chinese bayberry (Myrica rubra). BMC Genomics (2012) 1.08
Abnormal neural activities in first-episode, treatment-naïve, short-illness-duration, and treatment-response patients with major depressive disorder: a resting-state fMRI study. J Affect Disord (2011) 1.06
Reg4 protects against acinar cell necrosis in experimental pancreatitis. Gut (2010) 1.06
Genetic regulation of endotoxin-induced airway disease. Genomics (2004) 1.06
Genome-wide expression analysis of iron regulation in Burkholderia pseudomallei and Burkholderia mallei using DNA microarrays. FEMS Microbiol Lett (2005) 1.05
Radiographic and anatomic basis for prostate contouring errors and methods to improve prostate contouring accuracy. Int J Radiat Oncol Biol Phys (2009) 1.05
A review of Omics research in acupuncture: the relevance and future prospects for understanding the nature of meridians and acupoints. J Ethnopharmacol (2012) 1.04
The limits of log-ratios. BMC Biotechnol (2004) 1.04
Identification of miRNAs and their target genes in developing maize ears by combined small RNA and degradome sequencing. BMC Genomics (2014) 1.04
The bacterial effector VopL organizes actin into filament-like structures. Cell (2013) 1.04
The cocktail party problem. Neural Comput (2005) 1.03
An integrated approach to segmentation and nonrigid registration for application in image-guided pelvic radiotherapy. Med Image Anal (2011) 1.03
Self-supported Li4Ti5O12-C nanotube arrays as high-rate and long-life anode materials for flexible Li-ion batteries. Nano Lett (2014) 1.03
MammoSite and interstitial brachytherapy for accelerated partial breast irradiation: factors that affect toxicity and cosmesis. Cancer (2004) 1.02
Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer. Urol Nurs (2006) 1.01
Surgery for contralateral acute epidural hematoma following acute subdural hematoma evacuation: five new cases and a short literature review. Acta Neurochir (Wien) (2012) 1.01
Initial analysis of Pro-Qura: a multi-institutional database of prostate brachytherapy dosimetry. Brachytherapy (2007) 1.01
microRNA-34 family and treatment of cancers with mutant or wild-type p53 (Review). Int J Oncol (2011) 1.00
The effect of high-mobility group box 1 protein on activity of regulatory T cells after thermal injury in rats. Shock (2009) 1.00
Bayesian decoding using unsorted spikes in the rat hippocampus. J Neurophysiol (2013) 0.99
The potential effect and mechanism of high-mobility group box 1 protein on regulatory T cell-mediated immunosuppression. J Interferon Cytokine Res (2010) 0.99
Malignant mixed müllerian tumor of the fallopian tube: report of two cases and review of literature. Arch Gynecol Obstet (2009) 0.99
Optical coherence tomography for whole eye segment imaging. Opt Express (2012) 0.98